Exploring Immunotherapy for Carcinoid and Pancreatic Neuroendocrine Tumors – Newswise (press release)
|
Exploring Immunotherapy for Carcinoid and Pancreatic Neuroendocrine Tumors
Newswise (press release) Newswise — New Brunswick, N.J. – September 5, 2017 – A clinical trial testing the immunotherapy drug pembrolizumab shows the drug to be well tolerated among patients who have carcinoid or pancreatic neuroendocrine tumors. Janice M. Mehnert, MD, … |
